Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (18344)	6/5/2006 3:21:52 PM
From: Jibacoa	Respond to of 23958

PCYC Opened with an upgap today. bigcharts.marketwatch.com It presented additional data and analyses supporting its decision to file an NDA for Xcytrin at the 2006 Annual ASCO meeting.Its abstract was selected by ASCO's Scientific Program Committee to be featured in the "2006 Best of ASCO Meetings" in June, which feature the premier abstracts representing the most relevant, cutting-edge research in oncology today. Xcytrin is used for patients of lung Ca with brain metastases. PCYC trades around 1.26x BV & the insiders have done some buying lately. The short position increased around 6% in the last months & it is now about 15x its daily volume.<g> With some good news PCYC could close some of its large downgap & bounce up to the $7 level.<g> bigcharts.marketwatch.com